Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Standard Dose
400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is listed in Drugs@FDA under application 062166 (ANDA).

Marketing status: Discontinued Active ingredient BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength OINTMENT;OPHTHALMIC - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM Sponsor PADAGIS US Submission history Latest submission status date: 2001-09-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is listed in Drugs@FDA under application 062166 (ANDA). Marketing status: Discontinued Active ingredient BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength OINTMENT;OPHTHALMIC - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM Sponsor PADAGIS US Submission history Latest submission status date: 2001-09-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.